The double-blind, placebo-controlled study was conducted in patients suffering from platinum-sensitive epithelial ovarian cancer in first relapse to evaluate farletuzumab (MORAb-003) combination therapy.
Morphotek president and CEO Dr. Nicholas Nicolaides said the company is disappointed with the results.
"Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer," Nicolaides added.
The post hoc exploratory analysis has determined an inclination toward improved PFS in few patient subsets.
Most common adverse events were believed to be coupled with the study chemotherapeutic agents besides few immune-mediated events associated with farletuzumab.
Company anticipates determining new development strategy subsequent to the additional analysis of the clinical results.